BRIGHT MINDS BIOSCIENCES INC (DRUG) Institutional Ownership Changes & 13F Activity
BRIGHT MINDS BIOSCIENCES INC (DRUG). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q1 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Vestal Point Capital, Lp, Deerfield Management Company, L.P., Ra Capital Management, L.P., Great Point Partners Llc, and Braidwell Lp.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| Wells Fargo & Company/Mn | Sell | -2,991 | -54.2% | 2,532 | $184.76K | Q1 2026 | Jul 08, 2026 |
| Adar1 Capital Management, Llc | Buy | +30,400 | +868.6% | 33,900 | $2.47M | Q1 2026 | May 18, 2026 |
| Bank Of America Corp | Buy | +4,347 | +28.8% | 19,422 | $1.42M | Q1 2026 | May 18, 2026 |
| California State Teachers Retirement System | Buy | +70 | +22.6% | 380 | $27.73K | Q1 2026 | May 18, 2026 |
| Vestal Point Capital, Lp | Buy | +492,319 | — | 492,319 | $35.92M | Q1 2026 | May 15, 2026 |
| Deerfield Management Company, L.P. | Buy | +283,000 | — | 283,000 | $20.65M | Q1 2026 | May 15, 2026 |
| Ra Capital Management, L.P. | Buy | +265,000 | — | 265,000 | $19.34M | Q1 2026 | May 15, 2026 |
| Great Point Partners Llc | Buy | +220,000 | — | 220,000 | $16.05M | Q1 2026 | May 15, 2026 |
| Braidwell Lp | Buy | +215,350 | +66.4% | 539,708 | $39.38M | Q1 2026 | May 15, 2026 |
| Driehaus Capital Management Llc | Buy | +162,874 | +60.4% | 432,515 | $31.56M | Q1 2026 | May 15, 2026 |
| Millennium Management Llc | Sell | -141,605 | -72.8% | 52,832 | $3.86M | Q1 2026 | May 15, 2026 |
| Janus Henderson Group Plc | Buy | +128,329 | +11.1% | 1,284,324 | $93.52M | Q1 2026 | May 15, 2026 |
| Wellington Management Group Llp | Buy | +122,989 | +898.5% | 136,677 | $9.97M | Q1 2026 | May 15, 2026 |
| Adage Capital Partners Gp, L.L.C. | Buy | +100,000 | +25.3% | 495,743 | $36.17M | Q1 2026 | May 15, 2026 |
| Balyasny Asset Management L.P. | Buy | +71,746 | +31.8% | 297,158 | $21.68M | Q1 2026 | May 15, 2026 |
| Perceptive Advisors Llc | Sell | -71,746 | -16.0% | 377,544 | $27.55M | Q1 2026 | May 15, 2026 |
| B Group, Inc. | Buy | +67,500 | — | 67,500 | $4.93M | Q1 2026 | May 15, 2026 |
| Vivo Capital, Llc | Buy | +55,555 | +11.1% | 557,172 | $40.66M | Q1 2026 | May 15, 2026 |
| Woodline Partners Lp | Buy | +45,668 | — | 45,668 | $3.33M | Q1 2026 | May 15, 2026 |
| Parkman Healthcare Partners Llc | Buy | +40,098 | — | 40,098 | $2.93M | Q1 2026 | May 15, 2026 |
| Orbimed Advisors Llc | Buy | +40,000 | — | 40,000 | $2.92M | Q1 2026 | May 15, 2026 |
| State Street Corp | Buy | +30,961 | +40.1% | 108,239 | $7.90M | Q1 2026 | May 15, 2026 |
| Acuta Capital Partners, Llc | Buy | +27,519 | +32.6% | 111,996 | $8.17M | Q1 2026 | May 15, 2026 |
| Eventide Asset Management, Llc | Buy | +27,000 | +26.2% | 130,013 | $9.49M | Q1 2026 | May 15, 2026 |
| Goldman Sachs Group Inc | Buy | +25,822 | +53.2% | 74,369 | $5.43M | Q1 2026 | May 15, 2026 |
| Geode Capital Management, Llc | Buy | +25,170 | +39.6% | 88,716 | $6.47M | Q1 2026 | May 15, 2026 |
| Mpm Bioimpact Llc | Sell | -17,972 | -7.8% | 212,175 | $15.48M | Q1 2026 | May 15, 2026 |
| Schonfeld Strategic Advisors Llc | Sell | -16,967 | -56.2% | 13,244 | $966.41K | Q1 2026 | May 15, 2026 |
| D. E. Shaw & Co., Inc. | Buy | +11,528 | +294.3% | 15,445 | $1.13M | Q1 2026 | May 15, 2026 |
| Ghisallo Capital Management Llc | Buy | +11,000 | — | 11,000 | $802.67K | Q1 2026 | May 15, 2026 |
Frequently asked questions about DRUG activity
Which institutional owners are buying DRUG?
Institutional owners buying DRUG include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in DRUG activity?
"Buy" means an investor increased their reported position in DRUG compared to the prior reporting period. This reflects growing exposure to BRIGHT MINDS BIOSCIENCES INC (DRUG) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in DRUG increasing?
Institutional interest in DRUG can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.
Related DRUG Institutional Insights
- DRUG Overview
- DRUG 13F Institutional Holders
- DRUG Superinvestors
- Healthcare Sector Institutional Ownership
- Healthcare Sector Portfolio Overlap
- Institutional Portfolio Overlap & Shared Holdings
- Most Bought Healthcare Stocks By Institutional Investors
- Most Sold Healthcare Stocks By Institutional Investors
- DRUG Insider Trading & SEC Form 4 Activity
- DRUG Articles
- Top Institutional Investor Stock Rankings